Molecular Oncology, EarlyView.This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci +6 more
wiley +1 more source
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. [PDF]
Immunol Rev, 2023 Dreismann AK +6 more
europepmc +1 more source
Complement Activation in Semisolid Media: Insolubilization of Alternative Pathway Convertases in Agar Gels with C3 Nephritic Factor-Containing Sera [PDF]
, 1977 Mohammed A. Arnaout +3 more
openalex +1 more source
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Minimal role for the alternative pathway in complement activation by HIT immune complexes. [PDF]
J Thromb Haemost, 2022 Barnes AP +11 more
europepmc +1 more source
Alternative Pathways of Deoxyadenosine and Adenosine Metabolism
, 1973 Floyd F. Snyder, Jane Henderson
openalex +1 more source
Stimulation of Prostaglandin Synthesis with Resultant Bone Resorption by the Classical and Alternative C Pathways [PDF]
, 1976 Ann L. Sandberg +3 more
openalex +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source